Can-Fite BioPharma (CANF) Competitors $0.98 -0.03 (-2.97%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$0.98 +0.01 (+0.51%) As of 07/25/2025 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CANF vs. ERNA, PMN, LPTX, BFRG, SNPX, NEUP, FLGC, NERV, HOOK, and IMCCShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Ernexa Therapeutics (ERNA), Promis Neurosciences (PMN), Leap Therapeutics (LPTX), Bullfrog AI (BFRG), Synaptogenix (SNPX), Neuphoria Therapeutics (NEUP), Flora Growth (FLGC), Minerva Neurosciences (NERV), HOOKIPA Pharma (HOOK), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Its Competitors Ernexa Therapeutics Promis Neurosciences Leap Therapeutics Bullfrog AI Synaptogenix Neuphoria Therapeutics Flora Growth Minerva Neurosciences HOOKIPA Pharma IM Cannabis Ernexa Therapeutics (NASDAQ:ERNA) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Which has more volatility & risk, ERNA or CANF? Ernexa Therapeutics has a beta of 5.3, indicating that its stock price is 430% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Is ERNA or CANF more profitable? Can-Fite BioPharma has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics-7,652.75% N/A -285.71% Can-Fite BioPharma N/A N/A N/A Do institutionals and insiders have more ownership in ERNA or CANF? 70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 1.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to ERNA or CANF? In the previous week, Ernexa Therapeutics had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 1 mentions for Ernexa Therapeutics and 0 mentions for Can-Fite BioPharma. Ernexa Therapeutics' average media sentiment score of 1.87 beat Can-Fite BioPharma's score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Ernexa Therapeutics Very Positive Can-Fite BioPharma Neutral Which has better valuation & earnings, ERNA or CANF? Can-Fite BioPharma has higher revenue and earnings than Ernexa Therapeutics. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErnexa Therapeutics$580K24.74-$44.54M-$8.31-0.23Can-Fite BioPharma$674K5.15-$7.63M-$1.79-0.55 Do analysts recommend ERNA or CANF? Can-Fite BioPharma has a consensus price target of $14.00, suggesting a potential upside of 1,328.57%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Ernexa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCan-Fite BioPharma beats Ernexa Therapeutics on 8 of the 15 factors compared between the two stocks. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.47M$789.68M$5.70B$21.03BDividend YieldN/A4.84%4.58%3.59%P/E Ratio-0.551.4128.3928.45Price / Sales5.1524.88430.0871.66Price / CashN/A19.5636.2222.92Price / Book0.566.918.674.68Net Income-$7.63M-$4.13M$3.25B$995.51M7 Day Performance-5.31%1.01%4.30%1.65%1 Month Performance-5.31%3.65%10.57%4.54%1 Year Performance-73.58%9.83%35.68%10.00% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma1.9841 of 5 stars$0.98-3.0%$14.00+1,328.6%-71.7%$3.47M$674K-0.558ERNAErnexa Therapeutics1.0615 of 5 stars$1.96-1.0%N/A-92.8%$14.58M$580K-0.2410Positive NewsGap UpPMNPromis Neurosciences2.9604 of 5 stars$1.12+154.5%$4.33+286.9%-51.1%$14.39MN/A-22.405News CoverageAnalyst RevisionHigh Trading VolumeLPTXLeap Therapeutics2.0967 of 5 stars$0.34-1.5%$3.38+895.6%-83.4%$14.26MN/A-0.2040Positive NewsGap DownBFRGBullfrog AI0.4298 of 5 stars$1.50-0.7%N/A-52.8%$14.22M$60K-1.854High Trading VolumeSNPXSynaptogenix0.037 of 5 stars$10.11+7.6%N/A+115.0%$14.05MN/A-1.004High Trading VolumeNEUPNeuphoria Therapeutics1.8629 of 5 stars$7.70+3.4%$21.00+172.7%N/A$14.01M$10K0.00N/ANews CoveragePositive NewsAnalyst UpgradeFLGCFlora Growth2.6337 of 5 stars$0.65+4.4%$4.00+517.3%-46.5%$14M$59.51M-0.66280Positive NewsNERVMinerva Neurosciences4.4029 of 5 stars$1.95-2.0%$5.00+156.3%-31.7%$13.92MN/A2.389Positive NewsHOOKHOOKIPA Pharma3.0658 of 5 stars$1.04-8.8%$4.50+332.7%-85.4%$13.90M$43.95M-0.18160News CoverageHigh Trading VolumeIMCCIM Cannabis0.1208 of 5 stars$3.04-11.1%N/A+13.3%$13.83M$39.44M-4.75340News CoverageAnalyst UpgradeGap Down Related Companies and Tools Related Companies Ernexa Therapeutics Alternatives Promis Neurosciences Alternatives Leap Therapeutics Alternatives Bullfrog AI Alternatives Synaptogenix Alternatives Neuphoria Therapeutics Alternatives Flora Growth Alternatives Minerva Neurosciences Alternatives HOOKIPA Pharma Alternatives IM Cannabis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
